Cybin Inc. Common Stock Net Assets
Cybin Inc. Common Stock net assets. Based on the latest financial reports, Cybin Inc. Common Stock (HELP) has net assets worth $375.87 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($398.07 Million) and total liabilities ($22.20 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore HELP shareholders equity momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $375.87 Million |
| % of Total Assets | 94.42% |
| Annual Growth Rate | 130.98% |
| 5-Year Change | 175.44% |
| 10-Year Change | N/A |
| Growth Volatility | 1906.9 |
Net Assets of Cybin Inc. Common Stock (2017–2025)
Net assets of Cybin Inc. Common Stock from 2017 to 2025. This chart illustrates how Cybin Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. See how leveraged is Cybin Inc. Common Stock's balance sheet to measure how much of total assets are equity-financed.
Annual Net Assets for Cybin Inc. Common Stock (2017–2025)
The table below shows the annual net assets of Cybin Inc. Common Stock from 2017 to 2025. For live market cap and overall valuation, see Cybin Inc. Common Stock stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $237.20 Million | -18.75% |
| 2024-03-31 | $291.93 Million | +505.23% |
| 2023-03-31 | $48.23 Million | -36.66% |
| 2022-03-31 | $76.16 Million | -11.57% |
| 2021-03-31 | $86.12 Million | +5847.38% |
| 2020-03-31 | $1.45 Million | +266.84% |
| 2019-03-31 | $394.73K | -10.34% |
| 2018-03-31 | $440.25K | +50.37% |
| 2017-03-31 | $292.78K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cybin Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 33924078400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Cybin Inc. Common Stock Net Assets Breakdown (March 2025)
Cybin Inc. Common Stock net assets breakdown by equity component as of March 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $464.36 Million | 195.77% |
| Other Comprehensive Income | $-7.23 Million | -3.05% |
| Other Components | $119.44 Million | 50.35% |
| Total Equity | $237.20 Million | 100.00% |
Cybin Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Cybin Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Pacific Current Group Ltd
AU:PAC
|
$233.62 Million |
|
Acadian Timber Corp
TO:ADN
|
$233.67 Million |
|
Kaldalón hf.
IC:KALD
|
$233.70 Million |
|
Allogene Therapeutics Inc
NASDAQ:ALLO
|
$233.72 Million |
|
Okins Electronics Co. Ltd
KQ:080580
|
$233.50 Million |
|
Eaton Vance California MBF
NYSE MKT:EVM
|
$233.41 Million |
|
Shanghai Jin Jiang International Hotels Development Co Ltd B
SHG:900934
|
$233.38 Million |
|
MBIA Inc
NYSE:MBI
|
$233.28 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cybin Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 291,927,000 to 237,200,000, a change of -54,727,000 (-18.7%).
- Net loss of 113,137,000 reduced equity.
- New share issuances of 20,487,000 increased equity.
- Other comprehensive income decreased equity by 4,946,000.
- Other factors increased equity by 42,869,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-113.14 Million | -47.7% |
| Share Issuances | $20.49 Million | +8.64% |
| Other Comprehensive Income | $-4.95 Million | -2.09% |
| Other Changes | $42.87 Million | +18.07% |
| Total Change | $- | -18.75% |
Book Value vs Market Value Analysis
This analysis compares Cybin Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.40x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 5.76x to 0.40x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-03-31 | $0.81 | $4.68 | x |
| 2018-03-31 | $1.38 | $4.68 | x |
| 2019-03-31 | $1.08 | $4.68 | x |
| 2020-03-31 | $1.10 | $4.68 | x |
| 2021-03-31 | $32.72 | $4.68 | x |
| 2022-03-31 | $17.30 | $4.68 | x |
| 2023-03-31 | $9.88 | $4.68 | x |
| 2024-03-31 | $14.60 | $4.68 | x |
| 2025-03-31 | $11.73 | $4.68 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cybin Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -47.70%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.09x
- Recent ROE (-47.70%) is above the historical average (-61.39%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -43.38% | 0.00% | 0.00x | 1.51x | $-156.28K |
| 2018 | -50.15% | 0.00% | 0.00x | 1.04x | $-264.83K |
| 2019 | -25.59% | 0.00% | 0.00x | 1.03x | $-140.47K |
| 2020 | -134.25% | 0.00% | 0.00x | 1.18x | $-2.09 Million |
| 2021 | -37.41% | -3729.17% | 0.01x | 1.07x | $-40.83 Million |
| 2022 | -88.81% | 0.00% | 0.00x | 1.10x | $-75.25 Million |
| 2023 | -98.46% | 0.00% | 0.00x | 1.12x | $-52.31 Million |
| 2024 | -26.75% | 0.00% | 0.00x | 1.03x | $-107.27 Million |
| 2025 | -47.70% | 0.00% | 0.00x | 1.09x | $-136.86 Million |
Industry Comparison
This section compares Cybin Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $150,779,214
- Average return on equity (ROE) among peers: -66.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cybin Inc. Common Stock (HELP) | $375.87 Million | -43.38% | 0.06x | $233.50 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $25.47 Million |
| Abcellera Biologics Inc (ABCL) | $1.03 Billion | -0.22% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $14.83 Million | -365.49% | 3.32x | $238.46 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $16.14 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $30.03 Million | -30.65% | 0.08x | $724.08 Million |
| ABVC Biopharma Inc (ABVC) | $35.27K | -72.00% | 1.50x | $25.82 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $7.48 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $67.16 Million | -67.08% | 0.33x | $3.66 Billion |
About Cybin Inc. Common Stock
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical tr… Read more